Jonathan Ostrem, MD, PhD
Assistant Professor
Medicine
School of Medicine

Our laboratory uses chemical biology approaches to develop new modes of cancer therapy. We are interested in the design of small molecule and antibody-based cancer therapeutics directed at oncogenic signaling pathways. To accomplish this we use a variety of techniques, including synthetic organic chemistry, biochemistry, protein engineering, and cellular and mouse models of human cancer.

Awards

Show all (4) Hide

• Forbes 30 Under 30: Science & Healthcare, Forbes Magazine, 2014
• Joseph E. Mayer Award, University of California, San Diego, 2007
• Phi Beta Kappa, University of California, San Diego, 2007
• Thomas E. Curtis Scholarship, University of California, San Diego, 2006

Education & Training

Show all (4) Hide

• Medical Oncology Dana-Farber Cancer Institute, Harvard Medical School 06/2022
• Internal Medicine Brigham and Women's Hospital, Harvard Medical School 06/2018
• MD University of California, San Francisco 06/2016
• PhD Chemical Biology University of California, San Francisco 09/2013

Websites

Show all (1) Hide

• Ostrem Lab (ostremlab.ucsf.edu)

Grants and Projects

Show all (1) Hide

• Enhancing the precision of targeted therapies for EGFR-mutant lung cancer, Lung Cancer Research Foundation, 2022-2024

Publications (9)

Top publication keywords:
Octamer Transcription Factor-1Allosteric Regulationraf KinasesDrug DesignOncogene Protein p21(ras)Guanosine DiphosphateAntineoplastic AgentsAllosteric SiteGuanosine TriphosphateProtein Structure, SecondaryCytoplasmic DyneinsProto-Oncogene Proteins p21(ras)ThiamineMutant ProteinsStatic Electricity

• Direct RAS inhibitors turn 10.
  Nature chemical biology 2024 Ostrem JML, Peters U, Shokat KM
• Highly specific intracellular ubiquitination of a small molecule.
  bioRxiv : the preprint server for biology 2024 Li W, Garcia-Rivera EM, Mitchell DC, Chick JM, Maetani M, Knapp JM, Matthews GM, Shirasaki R, de Matos Simoes R, Viswanathan V, Pulice JL, Rees MG, Roth JA, Gygi SP, Mitsiades CS, Kadoch C, Schreiber …
• Rational Screening for Cooperativity in Small-Molecule Inducers of Protein-Protein Associations.
  Journal of the American Chemical Society 2023 Liu S, Tong B, Mason JW, Ostrem JM, Tutter A, Hua BK, Tang SA, Bonazzi S, Briner K, Berst F, Zécri FJ, Schreiber SL
• Rational screening for cooperativity in small-molecule inducers of protein-protein associations.
  bioRxiv : the preprint server for biology 2023 Liu S, Tong B, Mason JW, Ostrem JM, Tutter A, Hua BK, Tang SA, Bonazzi S, Briner K, Berst F, Zécri FJ, Schreiber SL
• Overcoming KRAS-Mutant Lung Cancer.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2022 Luo J, Ostrem J, Pellini B, Imbody D, Stern Y, Solanki HS, Haura EB, Villaruz LC

Show all (4 more) Hide

• Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.
  Nature reviews. Drug discovery 2016 Ostrem JM, Shokat KM
• A Ras-like domain in the light intermediate chain bridges the dynein motor to a cargo-binding region.
  eLife 2014 Schroeder CM, Ostrem JM, Hertz NT, Vale RD
• OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin.
  Proceedings of the National Academy of Sciences of the United States of America 2014 Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA, Li S, Xu L, Keshari KR, Lin MJ, Chien HC, Zhang Y, Morrissey KM, Liu J, Ostrem J, Younger NS, Kurhanewicz J, Shokat KM, Ashrafi K, Giacomini KM
• K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
  Nature 2013 Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM